Palliative and Supportive Care

cambridge.org/pax

The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study

Alessio Cortellini, M.D.[1,2], Giampiero Porzio, M.D.[1,2], Eva K. Masel, M.D., PH.D. M.SC.[3], Anna S. Berghoff, M.D., PH.D.[4], Barbara Knotzer, M.D.[3], Alessandro Parisi, M.D.[1,2], Francesco Pavese, M.D.[1,2], Corrado Ficorella, M.D.[1,2] and Lucilla Verna, M.D.[2]

[1]Medical Oncology Unit, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy; [2]Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; [3]Clinical Division of Palliative Care, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria and [4]Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

Original Article

Cite this article: Cortellini A, Porzio G, Masel EK, Berghoff AS, Knotzer B, Parisi A, Pavese F, Ficorella C, Verna L (2019). The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. *Palliative and Supportive Care* **17**, 82–86. https://doi.org/10.1017/S1478951518000238

Received: 18 December 2017
Revised: 26 February 2018
Accepted: 17 March 2018

Author for correspondence:
Alessio Cortellini, M.D., Medical Oncology Unit, St. Salvatore Hospital, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. E-mail: alessiocortellini@gmail.com

Introduction

One of the first steps to early integrate palliative care into oncology practice is a timely and efficient evaluation of symptoms (Bakitas et al., 2015; Davis et al., 2015; Temel et al., 2010). In a recent position paper, the Italian Association of Medical Oncology tells oncologists that they "must be able to prevent, recognize, measure, and treat all cancer-related symptoms" (Zagonel et al., 2017). Major international scientific societies such as the American Society of Clinical Oncology and the European Society of Medical Oncology have often defined the key role of symptoms evaluation and management to force the integration of palliative care into oncology (Davis et al., 2015; Ferrel et al., 2017). Nevertheless, a recent survey conducted by the Italian Association of Medical Oncology shows that only 20% of oncologists regularly uses valid tools to evaluate symptoms, 45% exclusively use them in the context of clinical trials, 30% use them only occasionally, and 5% never use them (Zagonel et al., 2016).

These data confirm what we and other authors have previously published (Giusti et al., 2017; Porzio et al., 2005a); we could say that, notwithstanding the effort that scientific societies put forth to promote early palliative care, few changes have been observed in terms of oncologists attitude toward a systematic evaluation of symptoms. That oncologists are mainly focused on disease-oriented therapies and that there is a lack of time in routine practice to evaluate symptoms may explain why there are still barriers in providing palliative care at an early time point. Some experiences reported that in an ambulatory oncology setting the average time spent to visit a patient during a chemotherapy session is 15 minutes (Grávalos et al., 2012; Greer et al., 2013). Thus, there is a need of simple and quick tools that enable a timely and efficient evaluation of symptoms. Recently, a newly designed questionnaire assesses seven items: pain, eating (loss of appetite/weight loss), rehabilitation (physical impairment), social situation (possibility for home care), suffering (anxiety/burden of disease/depression), O2 (dyspnea), and nausea/emesis (PERS^{2}ON) has shown to be feasible for symptom assessment in a palliative care setting (Masel et al., 2016). PERS^{2}ON works on a scale ranging from 0 (absence) to 10 (worst imaginable), resulting in a score ranging from 0 to 70. Given the characteristics of PERS^{2}ON as a user-friendly and fast tool, we tested its applicability in a simultaneous care context with patients on active treatment. The objective of our study was to evaluate the feasibility of a modified pain, eating (loss of appetite), rehabilitation (asthenia), sleep (sleep disorders), O$^{(2)}$ (dyspnea, cough), nausea/vomiting, and suffering (anxiety/depression) (PERSONS) score, changing just one item and replacing social situation with sleep because this seemed to be more feasible in the outpatient care setting.

Materials and methods

The PERSONS score

Each item on the PERSONS score is rated on a numeric scale between 0 (no burden) and 10 (worst imaginable burden). All seven points are summed, resulting in an overall score between 0 and 70. According to an assessment plan, for scores 0–3, the symptom was considered mild; for scores 4–6, the symptom was considered moderate; and for scores >7, the symptom was considered serious. The original scoring sheet is provided in Figure 1.

Patient eligibility

This prospective, single-institution, single-arm, pilot study evaluated consecutive advanced cancer patients who underwent a systemic disease-oriented therapy (chemotherapy and/or biological agents, intravenous and/or oral), regardless of treatment line, at the Medical

© Cambridge University Press 2018

CAMBRIDGE UNIVERSITY PRESS

The modified PERSONS score, Medical Oncology Unit – St, Salvatore Hospital

Patient:	Cycle:						Date:				
Pain	0	1	2	3	4	5	6	7	8	9	10
Eating	0	1	2	3	4	5	6	7	8	9	10
Rehabilitation	0	1	2	3	4	5	6	7	8	9	10
Sleep	0	1	2	3	4	5	6	7	8	9	10
Oxygen	0	1	2	3	4	5	6	7	8	9	10
Nausea/Vomiting	0	1	2	3	4	5	6	7	8	9	10
Suffering	0	1	2	3	4	5	6	7	8	9	10

Fig. 1. The PERSONS score.

Oncology Units of St. Salvatore University Hospital in L'Aquila. Patients were eligible if they had histologically confirmed diagnosis of advanced cancer, Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤2 and life expectancy >3 months. Comorbidities were evaluated by Cumulative Index Rating Scale (CIRS) (Extermann et al., 1998). Patients were stratified by number of metastatic sites (≤ or >2), primary tumor, and number of previous treatment lines. Patients were also stratified by level of schooling in three categories: those who completed elementary/middle school, those who completed high school and those who graduated. All patients provided written, informed consent to the proposed treatment. The procedures followed were in accordance with principles embodied in the Declaration of Helsinki and with the ethical standards of local responsible committees on human experimentation (Bioethics Committee).

Study design

Patients were evaluated using the PERSONS score at three time points: at the beginning of treatment and one and two months after that. The questionnaires were never administered to the patients, but were completed by physicians during each "prechemotherapy" visit in the outpatient clinic; the oncologists interviewed patients for up to 5 minutes, asking them to assign a score to each item from 0 to 10. In case of symptoms considered mild, no interventions were planned; in case of symptoms considered moderate, the oncologist provided the most appropriate therapeutic adjustment; in case of symptoms considered severe, the patient was sent to the PC division, which was established within our medical oncology unit in May 2002 (Porzio et al., 2005b). The Kruskal-Wallis test was used to correlate primary tumor and education level to baseline PERSONS score and to evaluate the impact of primary tumor and education's level on median change of PERSONS score during time (Kruskal and Wallis, 1952). Mann-Whitney *U* test was used to correlate number of metastatic sites to the baseline PERSONS score and to evaluate its impact on median change of PERSONS score over time (Mann & Whitney, 1947). Spearman's rank correlation coefficient was used to correlate number of previous treatment lines to baseline PERSONS score and to evaluate its effect on median change of PERSONS score during time (Spearman, 1904). Paired t-test was used to evaluate the variation of median PERSONS score over time (David & Gunnink, 1997). A two-tailed significance level of 0.05 was applied. All statistical analysis was performed with statistical package for the social sciences 20.0 software (SPSS Inc., Chicago, IL).

Results

Patient features

From October 2016 to March 2017, 66 patients were enrolled. Median age was 67 (range 48–91); male/female ratio was 25/66. Twenty-six patients (39.4%) had an ECOG-PS 0, 31 (47.0%) had ECOG-PS 1, and 9 (13.6%) had ECOG-PS 2. Different primary tumors were colorectal cancer, 21 patients (31.8%); lung cancer, 14 patients (21.2%); breast cancer, 6 patients (9.1%); urothelial cancer, 5 patients (7.6%); pancreatic cancer, 5 patients (7.6%); gastric cancer, 4 patients (6.1%); melanoma, 3 patients (4.5%); prostate cancer, 2 patients (3.0%); and other cancers, 6 patients (9.1%). Fifty-seven patients (86.4%) underwent chemotherapy ± targeted agents; six patients (9.1%) underwent targeted therapy alone and three patients (4.5%) an immune checkpoint inhibitor. Eleven patients (16.7%) had primary CIRS stage cancer, 27 patients (40.9%) an intermediate CIRS stage cancer, and 28 patients (42.4%) a secondary one. Twenty-six patients (39.4%) had ≤2 metastatic sites and 40 patients (60.6%) had >2 metastatic sites. Median number of previous chemotherapy treatment lines was 1 (range 1–5). Table 1 lists patient features.

PERSONS score evaluations

Following if the scores of each item of any reported severity (0–10). Thirty-one patients (46.9%) reported pain (median 0, range 0–9), 38 patients (57.5%) experienced problems with eating (median 1, range 0–8), 59 patients (89.3%) reported asthenia (median 2, range 0–10), 49 patients (74.2%) reported sleep disorders (median 2, range 0–8), 52 patients (78.7%) reported dyspnea/cough (median 2, range 0–7), 16 patients (24.2%) experienced nausea and/or vomiting (median 0, range 0–5), and 51 patients

https://doi.org/10.1017/S1478951518000238 Published online by Cambridge University Press

(77.3%) reported anxiety/depression (median 2, range 0–8). The median baseline PERSONS score was 12 (range 0–41) (Table 2; Figure 2). No correlation of baseline PERSONS score and primary tumor ($p = 0.648$), level of education ($p = 0.298$), or number of metastatic sites ($p = 0.106$) was found. Interestingly, a statistically significant association was observed between number of previous treatment lines and baseline PERSONS score (Spearman correlation coefficient 0.280; $p = 0.023$). Median PERSONS score after 1 month of treatment was 11 (0–35) and 9 (0–40) after 2 months of treatment (Figure 2). Importantly, a statically significant median reduction ($p < 0.001$) from baseline to 1 month and from baseline to 2 months was observed ($p < 0.001$). No impact of primary tumor ($p = 0.437$), level of education ($p = 0.272$), number of metastatic sites ($p = 0.443$), or number of previous treatment lines (Spearman correlation coefficient –0.045; $p = 0.724$) on median change of PERSONS score from baseline to 2 months was observed. Focusing on each item, a statistically significant median reduction of the score was observed from baseline to 1 month and to 2 months in pain ($p = 0.037$ and $p = 0.011$, respectively) and in rehabilitation ($p = 0.011$ and $p = 0.035$, respectively). A statistically significant median reduction in O^2 (dyspnea) was observed at the first evaluation ($p = 0.048$), but not at the second one, even at the limit of significance ($p = 0.058$). Curiously, an impressive statistically significant median reduction in suffering was observed from baseline to 2 months, but not from baseline to 1 month ($p < 0.001$ and $p = 0.342$, respectively) (Table 2).

Table 1. Patient features

	Overall population ($n = 66$)	
	N	%
Median age, years (range)	67 (48–91)	
Median ECOG-PS (range)	1 (0–2)	
0	26	39.4
1	31	47.0
2	9	13.6
Gender		
Male	41	62.1
Female	25	37.9
Highest completed education		
Elementary/middle school	30	45.5
High school	24	36.4
University	11	16.7
Missing	1	1.5
Primary tumor		
Colorectal cancer	21	31.8
Lung cancer	14	21.2
Breast cancer	6	9.1
Bladder cancer	5	7.6
Pancreatic cancer	5	7.6
Gastric cancer	4	6.1
Melanoma	3	4.5
Prostate cancer	2	3.0
Other	6	9.1
Number of metastatic sites		
≤2	26	39.4
>2	40	60.6
CIRS stage		
Stable	11	16.7
Intermediate	27	40.9
Unstable	28	42.4
Number of previous treatment lines		
None	42	63.6
1	10	15.2
2	5	7.6
3	4	6.0
4	5	7.6

CIRS, Cumulative Index Rating Scale; ECOG-PS, Eastern Cooperative Oncology Group performance status.

Discussion

This study found the PERSONS score to be a feasible tool for symptom assessment and management in an oncological outpatient setting. To reach an efficient and early integration of palliative care into oncology, it is important to have a clear idea of what the main therapy goals are (Verna et al., 2016). One is the efficient and timely treatment of symptoms, independent from the state of the disease and the cause that has triggered the symptoms (disease and/or treatment). Having appropriate tools to evaluate symptoms that are also user-friendly and fast may allow to overcome these limitations, which hinder efficient integration between palliative care and oncology practice. Median PERSONS score was rather low in each evaluation, probably because of the patient selection. The study population came from the ambulatory setting, so the cumulative incidence of symptoms was lower than what commonly found in palliative care setting. The absence of a correlation between baseline PERSONS score and primary tumors, level of education, and number of metastatic sites makes it a tool that could be used for any patient. Referring to the statically significant median reduction from the baseline score to months 1 and 2, without impact of primary tumor, level of education, and number of metastatic sites, the PERSONS score seems to be a valid tool to screen and monitor symptoms in an outpatient cancer care setting. The only statistically significant relation of median change of the score was seen in the number of previously administered chemotherapy lines, probably because it correlates to a more advanced state of disease and thus with a worse burden of symptoms. Our data suggest that the PERSONS score could address these needs and could be a valid tool to evaluate symptoms in patients receiving active antineoplastic treatment. Indeed, it was well accepted by patients and was feasible to administer before the chemotherapy session as well as in the context of routine visits. Oncologists could administer the questionnaire rather quickly, while working on other standard clinical evaluations, because thanks to its intuitive name, it was easy to remember, so much so that sometimes the scoring sheet was not required. The administration of PERSONS was done by residents at their first year of residency; they did not need any

https://doi.org/10.1017/S1478951518000238 Published online by Cambridge University Press

Table 2. Median PERSONS score at baseline and 1 and 2 months after initiation of treatment

	Baseline, median (range)	1 month, median (range)	*p* value, baseline vs. 1 month*	2 months, median (range)	*p* value, baseline vs. 2 months*
PERSONS score	12 (0–41)	11 (0–35)	**<0.001**	9 (0–35)	**<0.001**
Pain	0 (0–9)	0 (0–8)	**0.037**	0 (0–8)	**0.011**
Eating	1 (0–8)	1 (0–7)	0.888	1 (0–7)	0.474
Rehabilitation	2 (0–10)	2 (0–9)	**0.011**	2 (0–8)	**0.035**
Sleep	2 (0–8)	1 (8–8)	0.639	1 (0–7)	**0.351**
O^2 (dyspnea)	2 (0–7)	2 (0–8)	**0.048**	1 (0–8)	0.058
Nausea/vomiting	0 (0–5)	0 (0–6)	0.526	0 (0–6)	0.148
Suffering	2 (0–8)	2 (0–8)	0.342	2 (0–7)	**<0.001**

*Paired t-test. Bold values indicate $p \leq 0.05$.




Fig. 2. Graphical representation of median PERSONS score at baseline and after 1 and 2 months. PERSONS, pain, eating, rehabilitation, sleep, $O^{(2)}$, nausea/vomiting, and suffering.

experience to undertake this task. Even if not every outpatient center has a palliative care consultant who could properly treat more severe symptoms, the PERSONS score could help oncologists focus on patient needs, devoting the best care to the worst manifestation of disease, not only to the oncological outcomes. Strengths of the study are the prospective nature, the centralized review of resulted overall scores, and standardized assessment plan of scores for mild (0–3), moderate (4–6), and serious symptoms (≥7). Limitations are the sample size, the noncomparative nature, and that, although the PERSONS score could be considered a good screening tool, not every outpatient cancer care center has a palliative care consultant to report more severe symptoms. Before the development of the questionnaire, a lower percentage of patients was sent to the PC division, and the PERSONS score became oncologists' common clinical practice in our institution. The PERSONS score seems simplistic when compared with established assessment measures such as the Edmonton Symptom Assessment Scale, probably because of the number of items (7 vs. 10). On closer perusal, these differences are smoothed. While Pain, eating, rehabilitation, sleep, $O^{(2)}$, and nausea/vomiting have a direct comparator, the item "suffering" is a collector for "depression," "anxiety," and "well being." In our opinion, a first screening may be sufficient to identify the emotional suffering of patients, but more time is then necessary to study it and provide adequate support out of the outpatient clinical practice. To confirm that PERSONS score could be a "smarter" tool in simultaneous care setting, we recently designed a prospective comparative trial of the PERSONS score with the Edmonton Symptom Assessment Scale, which is the most commonly used questionnaire for symptoms evaluation (Chang et al., 2000); the study is currently recruiting patients both in outpatient and in home care settings.

Conclusion

Our data seem to confirm the feasibility of the PERSONS score and its efficacy in screening and monitoring symptoms. This may improve integration between oncology and palliative care, and could also be useful in centers where there is limited availability of resources and manpower. The PERSONS score was easy to remember because of its name; therefore, it could be easily used in ambulatory oncology or in a home care setting. Further studies are required to validate the PERSONS score.

Conflicts of interest. The authors declare that they have no competing interests.

References

Bakitas MA *et al.* (2015) Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III Randomized Controlled Trial. *Journal of Clinical Oncology* **33**(13), 1438–1445.

Chang VT, Hwang SS, and Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. *Cancer* **88**(9), 2164–2171.

David HA and Gunnink JL (1997) The paired t test under artificial pairing. *The American Statistician* **51**(1), 9–12.

Davis MP, Strasser F and Cherny N (2015) How well is palliative care integrated into cancer care? A MASCC, ESMO, and EAPC Project. *Supportive Care in Cancer* **23**(9), 2677–2685.

Davis MP *et al.* (2015) A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. *Annals of Palliative Medicine* **16**(4), 99–121.

Extermann M *et al.* (1998) Comorbidity and functional status are independent in older cancer patients. *Journal of Clinical Oncology* **16**(4), 1582–1587.

Ferrell BR *et al.* (2017) Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology* **35**(1), 96–112.

https://doi.org/10.1017/S1478951518000238 Published online by Cambridge University Press

Giusti R *et al.* (2017) Knowledge and attitudes of young italian medical oncologists toward the approach and treatment of pain: no changes, despite the law. *Pain Medicine* **18**(9), 1822–1824.

Grávalos C *et al.* Spanish Society for Medical Oncology (SEOM). (2012) Functions and workload of medical oncologists in Spain. *Clinical & Translational Oncology* **14**(6), 423–429.

Greer JA *et al.* (2013) Early integration of palliative care services with standard oncology care for patients with advanced cancer. *CA: A Cancer Journal for Clinicians* **63**(5), 349–363.

Kruskal W and Wallis WA (1952) Use of ranks in one-criterion variance analysis. *Journal of the American Statistical Association* **47**(260), 583–621.

Mann HB and Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. *Annals of Mathematical Statistics* **18**(1), 50–60.

Masel EK *et al.* (2016) The PERS(2)ON score for systemic assessment of symptomatology in palliative care: a pilot study. *European Journal of Cancer Care* **25**(4), 544–550.

Porzio G *et al.* (2005a) Assessment and treatment of symptoms among Italian medical oncologists. *Supportive Care in Cancer* **13**(11), 865–869.

Porzio G *et al.* (2005b) The Supportive Care Task Force at the University of L'Aquila: 2-years experience. *Supportive Care in Cancer* **13**(6), 351–355.

Spearman C (1904) The proof and measurement of association between two things. *American Journal of Psychology* **15**, 72–101. Reprinted in *International Journal of Epidemiology* (2010) 39(5), 1137–50.

Temel JS *et al.* (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. *New England Journal of Medicine* **363**, 733–742. doi: 10.1056/NEJMoa1000678

Verna L *et al.* (2016) Integration between oncology and palliative care: does one size fit all? *Annals of Oncology* **27**(3), 549.

Zagonel V *et al.* AIOM Simultaneous and Continuous Care (SCC), Task Force: ESMO Italian DCs. (2017) Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (simultaneous care). *Tumori* **103**(1), 9–14.

Zagonel V *et al.* AIOM Simultaneous & Continuous Care (SCC) Task Force-ESMO-DCs. (2016) Early integration of palliative care in oncology practice: results of the Italian Association of Medical Oncology (AIOM) survey. *Journal of Cancer* **7**(14), 1968–1978.

https://doi.org/10.1017/S1478951518000238 Published online by Cambridge University Press